Netflix Inc. (#NFLX) was among the stocks that stood out on Tuesday as it moved notably higher by +5.21% and closed the session at $634.81. This upward movement has led Netflix\u2019s stock price to a new 52 week high price while its 52 week low is at $463.41. At the moment Netflix is up 17.40% on a year to date basis. Netflix’s hit show “Squid Game” was in the market\u2019s focus in the past days. During the show, a phone number was displayed as part of the story which apparently is the real number of a woman living in South Korea. After a number of real prank phone calls and text messages received from supposed viewers of the show, the owner of the telephone number insists to be unable to change it, as it is used for business. In this case, Netflix has offered to edit scenes and remove the telephone from the show. This move by Netflix was seen in a positive manner by investors thus was compensated. On the other hand Squid Games has seen tremendous success in viewership and is in the ranks for one of the best series played all time for the online video streamer. Netflix\u2019s ability to provide its subscribers with amusing content is still enduring. Expectations remain high for Netflix\u2019s financial performance and some analysts are keen to raise the company\u2019s future earnings projections. Netflix\u2019s earnings report comes up on the 19th<\/sup> of October and is worth looking out for.<\/p>\n\n\n\n Merck makes noise with antiviral pill<\/u><\/em><\/strong><\/p>\n\n\n\n Merck & Co., Inc. (#MRK) was also in the markets focus in the past days and on Tuesday had left behind -1.81% closing the session at $81.60. At the moment Merck\u2019s stock price is up +4.62% while its 52 week price range is between $68.38 and $84.56. Since the last days of September and moving into October, Merck\u2019s brand has made considerable noise within the media as the pharmaceutical company prepares the ground for the Molnupiravir antiviral pill to get clearance. Molnupiravir is a medicine that\u2019s given orally in a capsule and has been tested on people diagnosed with Covid-19. Molnupiravir prevents replication of SARS-CoV-2, the coronavirus that causes COVID-19, as according to Bloomberg it causes the machinery that reproduces the virus\u2019s genetic material to make mistakes, thereby rendering the copies defective. This can support the body\u2019s defensive system to not overreact and possibly handle the virus more effectively. We must note that more testing may have to be undertaken on larger group of participants to fully determine the pill\u2019s effectiveness and possible side effects. Yet the news remains very positive for the time being as this can be considered a step closer to handling the pandemic and removing fears among the masses. The Food and Drug Administration (FDA) has yet to provide approval for the use of emergency for Molnupiravir, but is reviewing the pill\u2019s data so far. If the pill is approved we may see increased price action volatility among the covid-19 vaccine stocks and of course Merck. Please note Merck\u2019s earnings report comes up on the 28th<\/sup> of October. <\/p>\n\n\n\n Facebook in for a ride with latest pressure?<\/u><\/em><\/strong><\/p>\n\n\n\n Facebook Inc. (#FB) started the week putting traders on notice for the days ahead. On Tuesday Facebook was up +2.06% closing the session at $332.96. At the moment, Facebook is up +21.89% on a year to date basis and its 52 week range is between $244.61 and $384.33. Former Facebook product manager Frances Haugen noted among media as \u201dthe whistleblower\u201d, has brought to light details on the company\u2019s internal research. According to Frances Haugen Facebook has failed on eliminating violence and that it has misinformed investors about these happenings. The former Facebook product manager testified in Senate on Tuesday on her allegations over the company\u2019s supposed negligence on some matters. Moreover in the past days a global outage suspended Facebook and its other platforms operations for hours. The company officially stated this was due to configuration changes.<\/p>\n\n\n\n
![](\"https:\/\/shared.gighl.com\/Morning-Pictures-2021\/Article%20images%20\/Equities\/october\/fb-06-10-2021.png\"alt=\"Title\" "\\"title\\"")
<\/p>\n\n\n\n